Objective To evaluate the feasibility, safety and efficacy of percutaneous balloon mitral valvuloplasy (PBMV) in patients with rheumatic mitral stenosis merging left atrial thrombosis.
Methods One hundred and four patients with mitral stenosis and thrombus in the left atrium were selected. All cases received warfarin orally every day for more than 3 months and low dosage urokinase intravenous dripx every day for 5 days before undergoing PBMV with Inoue single balloon technique. The procedural success rate, changes of haemodynamics and echocardiographic indices after PBMV and complication as systematic thromboembolism during follow-up were observed.
Results The procedural success rate was 100%. Mean left atrial pressure (LAPm) and mean mitrial valve pressure gradient (MVPG) decreased from (24.3±4.2) mm Hg and (17.6±4.9) mm Hg to (11.3±4.5) mm Hg (p<0.05) and (7.2±3.9) mm Hg (p<0.05), respectively. Left atrial diameter (LAD) decreased from (58.20±5.6) mm before PBMV to (48.5±5.8) mm 24 h after PBMV (p<0.05) nd (44.5±5.8) mm 6 months after PBMV (p<0.05). Mitral valve area (MVA) increased from (0.80±0.36) cm2 before PBMV to (1.88±0.34) cm2 24 h after PBMV (p<0.01) and (1.76±0.27) cm2 6 months after PBMV (p<0.01). Pulmonary pressure (PP) decreased from (72.8±15.6) mm Hg before PBMV to (43.2±13.2) mm Hg 24 h after PBMV (p<0.01) and (39.5±13.6) mm Hg 6 months after PBMV (p<0.05). No systemic thromboembolism occurred during and after PBMV.
Conlusions PBMV on patients with rheumatic mitral stenosis merging left atrial thrombosis is safe, feasible and effective after sufficient anticoagulation treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.